



Subset list of 2023 prescription drugs for affordability reviews, approved by the board March 19, 2025

Therapy class	Proprietary name(s)	Non-proprietary name
Migraine Products	Ajovy	Fremanezumab-vfrm
Neuromuscular agents	Botox	OnabotulinumtoxinA/Botulinum Toxin
Dermatologicals	Cosentyx	Cosentyx/ Cosentyx Senoready Pen/ Cosentyx Sensoready Pen(2)/secukinumab
Digestive Aids	Creon	Pancrelipase/Lipase/Protease/Amylase
Dermatologicals	Dupilumab	Dupilumab
Anticoagulants	Eliquis	Apixaban
Migraine Products	Emgality	Galcanezumab
Cardiovascular agents – misc.	Entresto	Sacubitril/Valsartan
Analgesics – anti-inflammatory	Humira	Humira/Humira Pen/ Humira (CF) Pen/Adalimumab
Antineoplastics and adjunctive therapies	Ibrance	Palbociclib
Antidiabetics	Jardiance	Empagliflozin
Antidiabetics	Mounjaro	Tirzepatide
Migraine Products	Nurtec	Rimegepant/rimegepant sulfate
Psychotherapeutic and neurological agents – misc.	Ocrevus	Ocrelizumab
Antivirals	Odefsey	Emtricitabine/Rilpivirine/Tenofovir Alafenamide
Antidiabetics	Ozempic	Semaglutide
Antineoplastics and adjunctive therapies	Perjeta	Pertuzumab
Analgesics – anti-inflammatory	Rinvoq	Upadacitinib
Antidiabetics	Rybelsus	Semaglutide
Dermatologicals	Taltz	Ixekizumab
Antiasthmatic and bronchodilator agents	Trelegy	Trelegy Ellipta/Fluticasone Umeclidin vilanter/Fluticasone Umeclidinum vilanterol
Dermatologicals	Tremfya	Guselkumab
Antidiabetics	Trulicity	Dulaglutide
Migraine Products	Ubrelvy	Ubrogepant
Antineoplastics and adjunctive therapies	Verzenio	Abemzciclib
Antipsychotics/antimanic agents	Vraylar	Cariprazine/Cariprazine HCl
Anticoagulants	Xarelto	Rivaroxaban